Evaluating the post-licensure effectiveness of a group B meningococcal vaccine in New Zealand: A multi-faceted strategy

Vaccine

Volumn 23, Issue 17-18, 2005, Pages 2231-2234

  Ameratunga, Shanthi ^a,c   MacMillan, Alex ^a   Stewart, Joanna ^a   Scott, David ^a   Mulholland, Kim ^b   Crengle, Sue ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c THE UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Effectiveness; Epidemiologic methods; Immunization programs; Meningococcal disease; Product surveillance, postmarketing; Vaccine

Indexed keywords

ANTIBIOTIC AGENT; MENINGOCOCCUS VACCINE;

BACTERIAL STRAIN; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; CONFERENCE PAPER; DRUG EFFICACY; DRUG SCREENING; DRUG SPECIFICITY; EPIDEMIC; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; INFECTION PREVENTION; LICENSING; MENINGOCOCCOSIS; NEISSERIA LACTAMICA; NEISSERIA MENINGITIDIS; NEW ZEALAND; NONHUMAN; OBSERVATION; POISSON DISTRIBUTION; POLYMERASE CHAIN REACTION; POPULATION; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REGRESSION ANALYSIS;

EID: 14844325683     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.01.048     Document Type: Conference Paper

References (11)

1. Martin D, McDowell R. The epidemiology of Meningococcal disease in New Zealand in 2003. Report prepared for the Ministry of Health by the Institute for Environmental Science & Research Limited (ESR). Wellington: Ministry of Health; 2004.
2. D. Martin, S. Walker, M. Baker, and D. Lennon New Zealand epidemic of Meningococcal disease identified by a strain with phenotype B:4:P1.4 J Infect Dis 177 1998 497 500
3. K. Sexton, D. Lennon, P. Oster, S. Crengle, D. Martin, and K. Mulholland The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic N Z Med J 117 2004 URL: http://www.nzma.org.nz/journal/ 117-1200/1015/
4. M.E. Halloran, I.M. Longini Jr., and C.J. Struchiner Design and interpretation of vaccine field studies Epidemiol Rev 21 1999 73 88
5. E. Miller, D. Salisbury, and M. Ramsay Planning, registration and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story Vaccine 20 2001 S58 S67
6. P. McCullagh, and J.A. Nelder Generalized linear models 2nd ed. 1989 Chapman & Hall Ltd. London
7. C.P. Noronha, C.J. Struchiner, and M.E. Halloran Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study Int J Epidemiol 24 5 1995 1050 1057 [comment]
8. S. Nishioka Effectiveness of BC meningococcal vaccine in Brazil Int J Epidemiol 25 5 1996 1102 1103 [comment]
9. C. Jeffries, D. Lennon, J. Stewart, and D. Martin Meningococcal disease in Auckland July 1992-June 1994 N Z Med J 112 1999 115 117
10. M. Baker, A. McNicholas, N. Garrett, N. Jones, J. Stewart, and V. Koberstein Household crowding a major risk factor for epidemic meningococcal disease in Auckland children Pediatr Infect Dis J 19 2000 983 990
11. C. Farrington Estimation of vaccine effectiveness using the screening method Int J Epidemiol 22 4 1993 742 746